WeVote
Log In

Bill

Bill

HB 5485

AN ACT ESTABLISHING A CAPTIVE INSURANCE COMPANY TO ADMINISTER A BULK PURCHASE AND DISTRIBUTION OF GLUCAGON-LIKE PEPTIDE-1 PRESCRIPTION DRUGS TO QUALIFYING INDIVIDUALS IN THIS STATE TO TREAT OBESITY.

2025 Regular Session Introduced by Geoff Luxenberg

Connecticut would create a state insurance entity to buy GLP-1 obesity drugs in bulk and distribute them to qualifying residents, aiming to reduce costs and improve access.

REF. TO JOINT COMM. ON Insurance and Real Estate
#captiveinsurancecompanies #drugs #statefunds
0
WeVote Research Nonpartisan
Bill Summary · HB 5485

Legislative bill overview

HB 5485 proposes creating a state-operated captive insurance company in Connecticut to purchase GLP-1 drugs (like semaglutide/Ozempic and tirzepatide/Zepbound) in bulk and distribute them to qualifying state residents for obesity treatment. The bill aims to leverage bulk purchasing power to reduce costs and expand access to these high-demand medications that currently face supply constraints and affordability barriers.

Why is this important

GLP-1 drugs have become extremely expensive and difficult to access, with retail costs exceeding $1,000 monthly and insurance coverage varying widely. Connecticut's approach—using a captive insurance model—would be a novel state-level intervention to address medication affordability and could serve as a template for other states. This directly impacts thousands of residents struggling with obesity while facing financial or insurance barriers to treatment.

Potential points of contention

  • Cost and fiscal responsibility: Creating a new state insurance entity requires upfront capital and administrative infrastructure; unclear if bulk purchasing savings justify these expenses or if the program achieves projected cost reductions
  • Equity and eligibility criteria: Defining "qualifying individuals" raises questions about income thresholds, BMI requirements, and whether the program adequately serves vulnerable populations or becomes limited to specific demographics
  • Medical appropriateness and liability: GLP-1 drugs carry side effects and contraindications; the state bears liability risks if adverse outcomes occur, and questions arise about clinical oversight and provider participation requirements

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.